Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Outcomes Post Kidney Biopsy – Randomized Evaluation of Desmopressin
2021-006647-99Phase 3Active
- Sponsor
- Medical University of Białystok
- Start
- Mar 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of desmopressin in Glomerulonephritis (GN) (2 arms), sponsored by Medical University of Białystok. Primary endpoint: Efficacy primary outcome. Started Mar 2022; status: active.
02
Drugs
desmopressin
03
Conditions
Glomerulonephritis (GN)
Beyond the preview
Go deeper on 2021-006647-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006647-99.